糖尿病肾病治疗新药C66

本数据集包含药品稳定性情况，考察C66原料药（批号：C66-202009-3-7）在高温（60℃）、高湿（92.5%RH，25℃）、光照（可见光：4500±500lx，近紫外光：90μw/cm2）条件下性状、增失重、熔点、含量、有关物质、水分等的变化情况。以比格犬为例，考察了C66的一般药理学，从心电指标、血压变化和呼吸指标等因素入手进行药理学观察。药效学方面，关注了肾功能指标、血糖变化、肾脏组织切片染色图以及炎症因子表达的变化情况

This dataset contains stability-related data for the C66 active pharmaceutical ingredient (API) with batch number C66-202009-3-7. The stability was evaluated under three stress conditions: high temperature (60℃), high humidity (92.5% relative humidity (RH) at 25℃), and illumination (visible light: 4500 ± 500 lx; near-ultraviolet light: 90 μW/cm²), with monitored changes including appearance, weight gain/loss, melting point, assay content, related substances, and moisture content.

Taking Beagle dogs as the experimental model, the general pharmacology of C66 was investigated, and pharmacological observations were conducted based on indicators such as electrocardiographic parameters, blood pressure changes, and respiratory parameters.

In terms of pharmacodynamics, changes in renal function indicators, blood glucose levels, stained renal tissue sections, and the expression of inflammatory factors were assessed.

搜集汇总

背景与挑战

背景概述

该数据集提供了糖尿病肾病治疗新药C66的实验数据，包括原料药的稳定性测试、以比格犬为模型的一般药理学观察以及药效学指标分析。这些数据旨在评估C66化合物的性能，支持其作为新药的研发过程。